Mild Cognitive Impairment in Newly Diagnosed Parkinson's Disease: A Longitudinal Prospective Study
Overview
Authors
Affiliations
Introduction: In PD, Mild Cognitive Impairment (PD-MCI) occurs since early stages of disease. The aims were to assess presence of PD-MCI in untreated, drug-naive PD patients, and to follow-up the sample over 4 years to ascertain evolution of neurocognitive profile.
Methods: Seventy-six patients underwent neuropsychological testing at baseline (T0), and after 2 (T1:n = 62) and 4 years (T2:n = 55). Diagnosis of PD-MCI and PD-associated dementia (PDD) was made according to current consensus criteria.
Results: PD-MCI occurred in 25/76 patients (32.9%) at baseline, and 4 of them reverted from PD-MCI to Normal Cognition (Reverters), 7 remained stable (Non-Reverters) and 2 developed PDD at T2; 12 patients were lost to the follow-up. Among the 51 patients with normal cognition (PD-CN) at T0, 27 had normal cognition at T2 (5 of them were Reverters with respect to diagnosis at T1), 5 had MCI at T1 and T2 (Non-Reverters), 9 had MCI at T2 only, whereas 1 developed PDD; 9 patients were lost to the follow-up. At baseline, Reverters (n = 9) had younger age at onset and better performance on constructional visuospatial task than Non-Reverters (n = 12). Compared to patients without PD-MCI at all evaluations (n = 19), Reverters had poorer performance on verbal immediate recall and attention tasks and higher level of apathy at T0. Reduced performance on the Stroop Test at baseline predicted PD-MCI at T2.
Conclusion: Executive dysfunctions predicted development of PD-MCI after few years from onset. Reversal from PD-MCI to PD-CN was related to young age at onset and high level of apathy at baseline evaluation.
The role of on cognitive impairment in Parkinson's disease and Parkinsonisms.
Rosal A, Martin S, Strafella A Front Neurosci. 2025; 19:1515374.
PMID: 40052092 PMC: 11882537. DOI: 10.3389/fnins.2025.1515374.
Di Filippo F, De Biasi G, Russo M, Ricciardi C, Pisani N, Volzone A Sci Rep. 2025; 15(1):3371.
PMID: 39870679 PMC: 11772767. DOI: 10.1038/s41598-025-85118-8.
Liebert A, Bicknell B, Laakso E, Tilley S, Heller G, Kiat H BMC Neurol. 2024; 24(1):381.
PMID: 39385144 PMC: 11463085. DOI: 10.1186/s12883-024-03857-z.
Cognition and Activity of Daily Living Function in people with Parkinson's disease.
Bode M, Kalbe E, Liepelt-Scarfone I J Neural Transm (Vienna). 2024; 131(10):1159-1186.
PMID: 38976044 PMC: 11489248. DOI: 10.1007/s00702-024-02796-w.
Gupta S, Tielemans A, Guevara C, Huntley G, Benson D Proc Natl Acad Sci U S A. 2024; 121(28):e2317833121.
PMID: 38968112 PMC: 11252801. DOI: 10.1073/pnas.2317833121.